Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Clinical Study to Characterize Safety, Tolerability, and Pharmacokinetics of TR115 in Patients With Relapsed / Refractory Non-Hodgkin's Lymphoma or Advanced Solid Tumors

NCT05650580 is registered in ClinicalTrials.gov with Tarapeutics Science Inc. as lead sponsor.

NCT NCT05650580
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05650580 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Clinical Study to Characterize Safety, Tolerability, and Pharmacokinetics of TR115 in Patients With Relapsed / Refractory Non-Hodgkin's Lymphoma or Advanced Solid Tumors
Lead sponsor
Tarapeutics Science Inc.
Phase
Phase 1
Overall status
Unknown status
Start date
April 23, 2023
Completion date
December 30, 2025
Enrollment
26 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, non-hodgkin's lymphoma refractory, non-hodgkin's lymphoma, relapsed